-
公开(公告)号：US08518443B2
公开(公告)日：2013-08-27
申请号：US13535605
申请日：2012-06-28
IPC分类号： A61K9/20
CPC分类号： A61K9/2077 , A61K9/14 , A61K9/1635 , A61K9/1647 , A61K9/167 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/2086 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/44 , A61K31/445 , A61K31/46 , A61K31/485 , A61K45/06 , A61K47/32 , A61K47/38 , A61K2300/00
摘要： Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
-
2.发明授权Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent 有权含阿片样物质激动剂，阿片拮抗剂和胶凝剂的药物制剂公开(公告)号：US07842307B2
公开(公告)日：2010-11-30
申请号：US10214413
申请日：2002-08-06
IPC分类号： A61K9/127
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1635 , A61K9/1647 , A61K9/2027 , A61K9/205 , A61K9/2081 , A61K9/5078 , A61K47/10 , A61K47/32 , A61K47/36
摘要： Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
摘要翻译： 在某些实施方案中公开的是口服剂型，其包含治疗有效量的阿片类止痛剂，阿片样物质拮抗剂和一种或多种药学上可接受的赋形剂; 所述剂型还包括有效量的胶凝剂，以使得不适于施用的粘度，所述粘度选自肠胃外和鼻内施用于当所述剂型粉碎时形成的溶解混合物，并与约0.5至约10ml 的水性液体。
-
公开(公告)号：US07141250B2
公开(公告)日：2006-11-28
申请号：US10213920
申请日：2002-08-06
CPC分类号： A61K9/2013 , A61K9/205 , A61K9/2054
摘要： Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter taste to an abuser upon administration of said dosage form after tampering.
-
公开(公告)号：US20060182801A1
公开(公告)日：2006-08-17
申请号：US11352900
申请日：2006-02-13
IPC分类号： A61K31/485 , A61K9/20
CPC分类号： A61K31/485 , A61K9/0087 , A61K9/20 , A61K9/5084 , A61K31/46 , A61K45/06 , A61K2300/00
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.
-
5.发明授权Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent 有权含有阿片样物质激动剂，阿片拮抗剂和胶凝剂的药物制剂公开(公告)号：US08524275B2
公开(公告)日：2013-09-03
申请号：US12909527
申请日：2010-10-21
CPC分类号： A61K31/485 , A61K9/0053 , A61K9/1635 , A61K9/1647 , A61K9/2027 , A61K9/205 , A61K9/2081 , A61K9/5078 , A61K47/10 , A61K47/32 , A61K47/36
摘要： Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.
摘要翻译： 在某些实施方案中公开的是口服剂型，其包含治疗有效量的阿片类止痛剂，阿片样物质拮抗剂和一种或多种药学上可接受的赋形剂; 所述剂型还包括有效量的胶凝剂，以使得不适于施用的粘度，所述粘度选自肠胃外和鼻内施用于当所述剂型粉碎时形成的溶解混合物，并与约0.5至约10ml 的水性液体。
-
公开(公告)号：US08465774B2
公开(公告)日：2013-06-18
申请号：US11352900
申请日：2006-02-13
IPC分类号： A61K9/14
CPC分类号： A61K31/485 , A61K9/0087 , A61K9/20 , A61K9/5084 , A61K31/46 , A61K45/06 , A61K2300/00
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean Cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean Cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.
-
公开(公告)号：US20120108622A1
公开(公告)日：2012-05-03
申请号：US13349449
申请日：2012-01-12
IPC分类号： A61K31/485 , A61P25/36 , A61P25/04
CPC分类号： A61K9/2054 , A61J3/10 , A61K8/731 , A61K9/0002 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/06 , A61K9/08 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/19 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2095 , A61K9/28 , A61K9/2806 , A61K9/2813 , A61K9/284 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2893 , A61K9/48 , A61K9/4808 , A61K9/4833 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/4875 , A61K9/4891 , A61K9/5047 , A61K9/5078 , A61K9/5089 , A61K9/70 , A61K31/137 , A61K31/167 , A61K31/192 , A61K31/439 , A61K31/4458 , A61K31/48 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38
摘要： Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
摘要翻译： 在某些实施方案中公开了一种控释口服剂型，其包含治疗有效量的易于与一种或多种药学上可接受的赋形剂一起滥用的药物; 所述剂型还包括有效量的胶凝剂，以使得不适于施用的粘度，所述粘度选自肠胃外和鼻内施用于当所述剂型粉碎时形成的溶解混合物，并与约0.5至约10ml 的水性液体; 所述剂型在口服施用于人类患者时提供至少约12小时的治疗效果。
-
8.发明授权公开(公告)号：US07914818B2
公开(公告)日：2011-03-29
申请号：US10213919
申请日：2002-08-06
IPC分类号： A61K9/22
CPC分类号： A61K9/2077 , A61K9/14 , A61K9/1635 , A61K9/1647 , A61K9/167 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/2086 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/44 , A61K31/445 , A61K31/46 , A61K31/485 , A61K45/06 , A61K47/32 , A61K47/38 , A61K2300/00
摘要： Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
摘要翻译： 公开了口服剂型，其包含（i）治疗有效量的阿片样物质激动剂; （ii）可释放形式的阿片拮抗剂; 和（iii）当所述剂型完全施用时不释放的螯合阿片样物质拮抗剂及其方法。
-
公开(公告)号：US20160058716A1
公开(公告)日：2016-03-03
申请号：US14852236
申请日：2015-09-11
IPC分类号： A61K31/137 , A61K9/48 , A61K9/16 , A61K9/00
CPC分类号： A61K9/2054 , A61J3/10 , A61K8/731 , A61K9/0002 , A61K9/0053 , A61K9/006 , A61K9/0095 , A61K9/06 , A61K9/08 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/19 , A61K9/20 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2095 , A61K9/28 , A61K9/2806 , A61K9/2813 , A61K9/284 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2893 , A61K9/48 , A61K9/4808 , A61K9/4833 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K9/4875 , A61K9/4891 , A61K9/5047 , A61K9/5078 , A61K9/5089 , A61K9/70 , A61K31/137 , A61K31/167 , A61K31/192 , A61K31/439 , A61K31/4458 , A61K31/48 , A61K31/485 , A61K45/06 , A61K47/02 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38
摘要： Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
-
10.发明申请公开(公告)号：US20120288567A1
公开(公告)日：2012-11-15
申请号：US13535605
申请日：2012-06-28
IPC分类号： A61K31/485 , A61P29/00 , A61K9/14
CPC分类号： A61K9/2077 , A61K9/14 , A61K9/1635 , A61K9/1647 , A61K9/167 , A61K9/2009 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/2086 , A61K9/5026 , A61K9/5078 , A61K9/5084 , A61K31/44 , A61K31/445 , A61K31/46 , A61K31/485 , A61K45/06 , A61K47/32 , A61K47/38 , A61K2300/00
摘要： Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
摘要翻译： 公开了口服剂型，其包含（i）治疗有效量的阿片样物质激动剂; （ii）可释放形式的阿片拮抗剂; 和（iii）当所述剂型完整施用时不释放的螯合阿片样物质拮抗剂及其方法。
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.03 秒)
